Form 8-K - Current report:
SEC Accession No. 0001819790-25-000003
Filing Date
2025-01-17
Accepted
2025-01-17 17:08:58
Documents
13
Period of Report
2025-01-15
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K tars-20250115.htm   iXBRL 8-K 23999
  Complete submission text file 0001819790-25-000003.txt   146451

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT tars-20250115.xsd EX-101.SCH 1773
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT tars-20250115_lab.xml EX-101.LAB 21629
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT tars-20250115_pre.xml EX-101.PRE 12502
15 EXTRACTED XBRL INSTANCE DOCUMENT tars-20250115_htm.xml XML 2833
Mailing Address 15440 LAGUNA CANYON ROAD IRVINE CA 92618
Business Address 15440 LAGUNA CANYON ROAD IRVINE CA 92618 (949) 409-9820
Tarsus Pharmaceuticals, Inc. (Filer) CIK: 0001819790 (see all company filings)

EIN.: 814717861 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39614 | Film No.: 25539537
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)